A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Launched by BRISTOL-MYERS SQUIBB · May 27, 2009

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
• Inclusion Criteria:
• • Esophageal, gastric, or gastroesophageal adenocarcinoma that has spread and cannot be treated with surgery. The diagnosis must be confirmed by a trained pathologist.
• • Prior radiation therapy is allowed in certain circumstances - discuss with your doctor.
• • Individuals who have had surgery may be eligible after recovering from the procedure.
• • Individuals who have received chemotherapy for the treatment of their disease within the past 6 months are not eligible. Chemotherapy given more than 6 months ago is permitted.
• • Individuals with spread of their cancer to the brain are permitted in certain circumstances - talk with your doctor.
• Exclusion Criteria:
• • Significant heart disease.
• • Women pregnant or breastfeeding.
• • Women able to bear children who are unwilling or unable to use an acceptable method to avoid pregnancy.
• • Uncontrolled medical condition or active infection
• • Inability to swallow pills.
• • Inability to undergo a blood draw, in which a needle is used to obtain blood from a vein in your arm.
• • Individuals receiving another drug not approved by the Food and Drug Administration (FDA) or similar agency in another country.
• • Prisoners or individuals currently receiving treatment for a mental or physical illness as an inpatient in a hospital.
• • Individuals who have experienced pancreatitis, an inflammation of the pancreas, in the past, or who have had a computed axial tomography (CT) scan showing pancreatitis.